NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2025-013733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Kun Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, RNA, Long Noncoding, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
T-cell exhaustion induced by the tumor microenvironment is an important factor in posing a major challenge to effective cancer immunotherapy. Immune checkpoint inhibitors aim to reverse T-cell exhaustion. However, the effectiveness of immune checkpoint inhibitors is often limited due to their off-target effects and single targets. Herein, we attempt to identify molecular targets that can regulate the expression of multiple immune checkpoints to reverse T-cell exhaustion.
Methods
NSG mice with xenotransplantation of human bladder cancer cells were used to investigate the function of nuclear paraspeckle assembly transcript 1 (NEAT1) in T-cell exhaustion. Chromatin isolation by RNA purification, chromatin immunoprecipitation, and luciferase assays was employed to investigate the molecular mechanisms by which NEAT1 regulates expression of target genes.
Results
NEAT1, a bladder cancer-related long non-coding RNA (lncRNA), promotes lactate production in tumor cells by binding to the lactate dehydrogenase A gene. This lactate production subsequently inhibits NEAT1 expression in CD8+T cells. Furthermore, NEAT1 in CD8+T cells plays a crucial role in modulating the immune response of CD8+T cells against tumor cells. Our findings indicate that NEAT1 regulates the expression of multiple immune checkpoint genes by directly binding to them and inhibiting transcription through the alteration of histone lactylation near transcriptional start sites, which affects RNA polymerase II recruitment. Conclusions lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China.
- Biomedical Sciences College and Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Jinan, Shandong, China.
- Biomedical Sciences College and Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Jinan, Shandong, China yky2009@163.com jxhan9888@aliyun.com linwang@sdfmu.edu.cn.
- Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China yky2009@163.com jxhan9888@aliyun.com linwang@sdfmu.edu.cn.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, K., Niu, L., Zhang, X., Li, T., Zhou, X., Wang, L., Han, J., & Wang, Z. (2025). NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013733
Vancouver
Li K, Niu L, Zhang X, Li T, Zhou X, Wang L, et al. NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-013733
BibTeX
@article{Li2025,
author = {Li, Kun and Niu, Lixin and Zhang, Xufei and Li, Tianzi and Zhou, Xiaoyan and Wang, Lin and Han, Jinxiang and Wang, Ziqiang},
title = {NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2025-013733}
}
EUVIMED